Needham Maintains Buy on RxSight, Lowers Price Target to $7
Needham analyst David Saxon maintains RxSight (NASDAQ:RXST) with a Buy and lowers the price target from $11 to $7.
Share
Why It Matters
An expert thinks RxSight is still worth buying, but the stock might be worth less money now. When experts lower their price guess, watch if the company needs to do better.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.